These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29262541)

  • 21. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
    Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
    Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
    Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
    Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
    Nagaraj NS; Washington MK; Merchant NB
    Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
    Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
    Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of ER-Src axis in hormonal therapy resistance.
    Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
    Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Src as a Therapeutic Target in Biliary Tract Cancer.
    Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
    Messersmith WA; Rajeshkumar NV; Tan AC; Wang XF; Diesl V; Choe SE; Follettie M; Coughlin C; Boschelli F; Garcia-Garcia E; Lopez-Rios F; Jimeno A; Hidalgo M
    Mol Cancer Ther; 2009 Jun; 8(6):1484-93. PubMed ID: 19509264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
    Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
    Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
    Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
    Mashimo K; Tsubaki M; Takeda T; Asano R; Jinushi M; Imano M; Satou T; Sakaguchi K; Nishida S
    Clin Exp Med; 2019 Feb; 19(1):133-141. PubMed ID: 30291461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
    Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways.
    Bouchard V; Demers MJ; Thibodeau S; Laquerre V; Fujita N; Tsuruo T; Beaulieu JF; Gauthier R; Vézina A; Villeneuve L; Vachon PH
    J Cell Physiol; 2007 Sep; 212(3):717-28. PubMed ID: 17443665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of IKKβ/NF-κB signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.
    Yang Z; Liao J; Cullen KJ; Dan H
    Cell Death Discov; 2020; 6():36. PubMed ID: 32435511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
    Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition.
    Rose MM; Nassar KW; Sharma V; Schweppe RE
    Med Oncol; 2023 Sep; 40(10):299. PubMed ID: 37713162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of TGF-β Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors.
    Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnerta H; Ungefroren H
    Anticancer Agents Med Chem; 2017; 17(10):1351-1356. PubMed ID: 28044939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer.
    McKinley ET; Liu H; McDonald WH; Luo W; Zhao P; Coffey RJ; Hanks SK; Manning HC
    PLoS One; 2013; 8(11):e80207. PubMed ID: 24260357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dasatinib inhibits proliferation of liver cancer cells, but activation of Akt/mTOR compromises dasatinib as a cancer drug.
    Liu C; Zhu X; Jia Y; Chi F; Qin K; Pei J; Zhang C; Mu X; Zhang H; Dong X; Xu J; Yu B
    Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(7):823-836. PubMed ID: 33961012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
    Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
    Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.